rDNA drug applications at FDA
Some 30 to 40 rDNA-derived NDAs are "under consideration or anticipated for" review by FDA in fiscal year 1984, according to a recently released report on federal biotechnology activities commissioned by the Natl. Science Foundation. The report estimates that FDA will consider an additionl 100 rDNA NDAs in FY 1985 and review another 200 in FY 1986
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."